Shanghai Shyndec Pharmaceutical Co Ltd (600420) - Total Liabilities
Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) has total liabilities worth CN¥3.42 Billion CNY (≈ $500.87 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Shyndec Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Shanghai Shyndec Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Shyndec Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liberty Global PLC Class C
NASDAQ:LBTYK
|
USA | $12.43 Billion |
|
SRG Global Ltd
AU:SRG
|
Australia | AU$591.77 Million |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
China | CN¥1.02 Billion |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
USA | $369.03 Million |
|
Allied Gold Corporation
NYSE:AAUC
|
USA | $1.27 Billion |
|
FLEX LNG Ltd
NYSE:FLNG
|
USA | $1.90 Billion |
|
MicroPort Endovascular MedTech Ltd
SHG:688016
|
China | CN¥554.42 Million |
|
Digital China Information Service Co Ltd
SHE:000555
|
China | CN¥8.03 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Shanghai Shyndec Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600420 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Shyndec Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Shyndec Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Shanghai Shyndec Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-15.70 Billion ≈ $-2.30 Billion |
-438.80% |
| 2024-12-31 | CN¥4.63 Billion ≈ $678.05 Million |
-7.59% |
| 2023-12-31 | CN¥5.01 Billion ≈ $733.72 Million |
-32.95% |
| 2022-12-31 | CN¥7.48 Billion ≈ $1.09 Billion |
-14.05% |
| 2021-12-31 | CN¥8.70 Billion ≈ $1.27 Billion |
+3.19% |
| 2020-12-31 | CN¥8.43 Billion ≈ $1.23 Billion |
-0.05% |
| 2019-12-31 | CN¥8.44 Billion ≈ $1.23 Billion |
+5.17% |
| 2018-12-31 | CN¥8.02 Billion ≈ $1.17 Billion |
+6.62% |
| 2017-12-31 | CN¥7.52 Billion ≈ $1.10 Billion |
-6.86% |
| 2016-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
+219.77% |
| 2015-12-31 | CN¥2.53 Billion ≈ $369.60 Million |
+4.50% |
| 2014-12-31 | CN¥2.42 Billion ≈ $353.69 Million |
+32.78% |
| 2013-12-31 | CN¥1.82 Billion ≈ $266.38 Million |
+42.41% |
| 2012-12-31 | CN¥1.28 Billion ≈ $187.06 Million |
+134.68% |
| 2011-12-31 | CN¥544.70 Million ≈ $79.71 Million |
+82.76% |
| 2010-12-31 | CN¥298.05 Million ≈ $43.61 Million |
+39.12% |
| 2009-12-31 | CN¥214.24 Million ≈ $31.35 Million |
+31.11% |
| 2008-12-31 | CN¥163.41 Million ≈ $23.91 Million |
+36.66% |
| 2007-12-31 | CN¥119.57 Million ≈ $17.50 Million |
+38.80% |
| 2006-12-31 | CN¥86.15 Million ≈ $12.61 Million |
-19.24% |
| 2005-12-31 | CN¥106.67 Million ≈ $15.61 Million |
+43.54% |
| 2004-12-31 | CN¥74.32 Million ≈ $10.87 Million |
-37.60% |
| 2003-12-31 | CN¥119.11 Million ≈ $17.43 Million |
+33.98% |
| 2002-12-31 | CN¥88.90 Million ≈ $13.01 Million |
+10.19% |
| 2001-12-31 | CN¥80.67 Million ≈ $11.81 Million |
-- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more